Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Wave Life Sciences (WVE) Free Cash Flow: 2015-2025

Historic Free Cash Flow for Wave Life Sciences (WVE) over the last 11 years, with Sep 2025 value amounting to -$44.9 million.

  • Wave Life Sciences' Free Cash Flow rose 4.15% to -$44.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$198.2 million, marking a year-over-year decrease of 39.73%. This contributed to the annual value of -$152.0 million for FY2024, which is 639.63% down from last year.
  • Wave Life Sciences' Free Cash Flow amounted to -$44.9 million in Q3 2025, which was up 3.03% from -$46.3 million recorded in Q2 2025.
  • Wave Life Sciences' Free Cash Flow's 5-year high stood at $85.0 million during Q1 2023, with a 5-year trough of -$63.2 million in Q1 2025.
  • Its 3-year average for Free Cash Flow is -$29.7 million, with a median of -$37.3 million in 2023.
  • As far as peak fluctuations go, Wave Life Sciences' Free Cash Flow tumbled by 377.36% in 2022, and later skyrocketed by 312.15% in 2023.
  • Wave Life Sciences' Free Cash Flow (Quarterly) stood at -$7.0 million in 2021, then slumped by 377.36% to -$33.6 million in 2022, then grew by 0.15% to -$33.6 million in 2023, then crashed by 30.18% to -$43.7 million in 2024, then grew by 4.15% to -$44.9 million in 2025.
  • Its Free Cash Flow was -$44.9 million in Q3 2025, compared to -$46.3 million in Q2 2025 and -$63.2 million in Q1 2025.